<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Pfizer’s COVID-19 Candidate Has Moderate Side Effects
Image Overlay - Pfizer’s COVID-19 Candidate Has Moderate Side Effects

Pfizer’s COVID-19 Candidate Has Moderate Side Effects

Pfizer’s COVID-19 Candidate Has Moderate Side Effects

Pfizer has announced that participants in their phase III clinical trial had moderate side effects. More than 12,000 people have received a second round of the vaccine, with 29,000 enrolled in the trial. For phase III, Pfizer would like to increase enrollment to 44,000 including people as young as 16 and those with HIV and hepatitis C or B. Yourway’s primary and secondary packaging capabilities integrate seamlessly with our storage & distribution and premium courier services to enhance supply chain efficiency and facilitate shorter lead times compared to other clinical services and logistics companies.

Back to Index
Media

Upcoming Events

GCSG 2024 US Conference

April 21-24, 2024
Naples, Florida

Precision in Clinical Trials Summit (Boston)

May 6-7, 2024
Hilton Boston Park Plaza

Media

Articles

Regulatory barriers in cross-border European pharmaceutical transport

Open chat
Come chat with us!
Hello! How can I help you?